On August 7, 2024 Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided immunotherapies for the treatment of cancer, reported it has entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of solid tumors (Press release, MediGene, AUG 7, 2024, https://www.pressetext.com/news/20240808017 [SID1234645513]). The collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics’ anti-CD3 mAb, its TCE platform and proprietary bispecific antibody platform WuXiBody.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The companies aim to co-research TCR-TCE constructs, which will be owned by both cooperation partners with options to Medigene to further advance their development. The resulting constructs will leverage Medigene’s highly specific 3S TCRs for comprehensive target recognition, coupled with WuXi Biologics’ anti-CD3 mAb, bispecific antibody technology and TCE platform to activate T cells. The resultant bispecific therapeutics are expected to provide highly specific targeted immune responses that direct T cells to effectively attack and kill cancer cells while minimizing off-target effects, and thereby improve patient outcomes.